Adeno-Associated Virus Capsid Structure Drives CD4-Dependent CD8+ T Cell Response to Vector Encoded Proteins
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The immunological sequelae of adeno-associated virus (AAV)-mediated gene transfer in vivo is quite complex. In murine models, most AAV capsids are associated with minimal or dysfunctional T cell responses to antigenic transgene products. In this study we compared T cell activation against AAV2/8 and AAV2/rh32.33 vectors expressing nuclear-targeted LacZ (nLacZ), GFP, or firefly luciferase in murine skeletal muscle. We show that, unlike AAV8, AAVrh32.33 yields qualitatively and quantitatively robust T cell responses to both the capsid and transgene product. AAV2/rh32.33.CB.nLacZ, but not AAV2/8, drives a high degree of cellular infiltration and a loss of detectable transgene expression in C57BL/6 mice. However, cellular immunity to AAVrh32.33 is ablated in the absence of CD4, CD40L, or CD28, permitting stable β-galactosidase expression. Treatment of CD40L−/− mice with the CD40 agonist, FGK45, failed to restore the CD8 response to AAV2/rh32.33.nLacZ, suggesting that additional factors are involved. Our results suggest that specific domains within the AAVrh32.33 capsid augment the adaptive response to both capsid and transgene Ags in a CD4-dependent pathway involving CD40L signaling and CD28 costimulation. Structural comparison of the AAV8 and rh32.33 capsids has identified key differences that may drive differential immunity by affecting tropism, Ag presentation or the activation of innate immunity. This murine model of AAV-mediated cytotoxicity allows us to delineate the mechanism of viral immune activation, which is relevant to the translation of AAV technology in higher order species.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612
Jooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 1×
“a more immunogenic vector, such as adenovirus-expressing LacZ (44).”
BackgroundSelf-citationSnyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366
Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208 · cited 1×
“nLacZ elicits virtually no immune response to either nLacZ or the capsid, consistent with previous reports of aberrant T cell responses in mice (40, 41, 43).”
ResultSelf-citationStructurally mapping the diverse phenotype of adeno-associated virus serotype 4
Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A., & Agbandje-McKenna, M. (2006) · Journal of Virology · doi:10.1128/jvi.01536-06 · Cited by 205
Self-citation
Research works printed but not linked: 45
- 2005, Gene therapy: twenty-first century medicine., 711
- 2008, Immunity to adeno-associated virus vectors in animals and humans: a continued challenge., 808
- 1999, Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector., 56
- 2005, Helper functions required for wild type and recombinant adeno-associated virus growth., 265
- 1965, Association of 20-millimicron particles with adenoviruses., 271
- 1965, Adenovirus-associated defective virus particles., 754
- 1996, Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3., 208
- 2005, Structure of adeno-associated virus type 4., 5047
- 1998, Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2., 309
- 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy., 11854
- 2003, Adeno-associated viruses undergo substantial evolution in primates during natural infections., 6081
- 2004, Clades of adeno-associated viruses are widely disseminated in human tissues., 6381
- 2004, Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein., 375
- 2009, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses., 381
- 1966, Small deoxyribonucleic acid-containing viruses (picodnavirus group)., 331
- 1993, Structure, sequence, and function correlations among parvoviruses., 491
- 2007, Structure of adeno-associated virus serotype 8, a gene therapy vector., 12260
- 2000, Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism., 8635
- 2000, Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX., 225
- 2005, Systemic protein delivery by muscle-gene transfer is limited by a local immune response., 4226
- 2005, Immune responses to adeno-associated virus vectors., 323
- 2005, An optimized protocol for detection of E. coli β-galactosidase in lung tissue following gene transfer., 77
- 2006, The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling., 195
- 2004, Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions., 2256
- 2004, COOT: model-building tools for molecular graphics., 2126
- 1991, Improved methods for building protein models in electron density maps and the location of errors in these models., 110
- 2007, Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer., 1132
- 2001, Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors., 269
- 2001, The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice., 1813
- 1999, Immune response to green fluorescent protein: implications for gene therapy., 1305
- 2003, Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment., 4911
- 2003, Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection., 2053
- 1994, CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection., 8056
- 1995, Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse-models., 8178
- 1998, CTL effector function within the central nervous system requires CD4+ T cells., 2896
- 1998, Help for cytotoxic-T-cell responses is mediated by CD40 signalling., 478
- 1998, A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell., 474
- 2000, Immature dendritic cells acquire CD8+ cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli., 145
- 1996, Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation., 747
- 1996, CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40., 1862
- 2002, A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory., 2060
- 2000, CD40-independent pathways of T cell help for priming of CD8+ cytotoxic T lymphocytes., 541
- 2000, Role of CD40 ligand and CD28 in induction and maintenance of antiviral CD8+ effector T cell responses., 3689
- 2001, Role of CD28/CD80–86 and CD40/CD154 costimulatory interactions in host defense to primary herpes simplex virus infection., 612
- 1995, New perspectives of CD28–B7-mediated T cell costimulation., 555
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Progress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“Therefore, rAAV vectors bearing different capsids have different transduction potential, but also potentially different immunological properties (5, 30).”
BackgroundGene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
Hastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
CpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254
Self-citationMartino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246
Humoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243
“33 as vector for gene therapy, recent studies have shown this serotype induces a remarkable strong T cell mediated immune responses to the transgene product, similar to that induced by adenovirus, considerably limiting gene expression duration (48).”
Self-citationBucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215
“33 capsid and local infiltration of cytotoxic T cells into muscle in a TLR9-dependent manner (17, 24).”
Self-citationInnate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Adeno-Associated Virus (AAV) Versus Immune Response
Rabinowitz, J., Chan, Y. K., & Samulski, R. J. (2019) · Viruses · doi:10.3390/v11020102 · Cited by 122
“33 injection in mice results in a robust T cell response to both the capsid and the transgene product, this is unlike the T cell response to other AAV serotypes in mice [15].”
BackgroundHareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
Immune Response Mechanisms against AAV Vectors in Animal Models
Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97
Thwaite, R., Pagès, G., Chillón, M., & Bosch, A. (2015) · Gene Therapy · doi:10.1038/gt.2014.103 · Cited by 76
MyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV
Sudres, M., Ciré, S., Vasseur, V., Brault, L., Da Rocha, S., Boisgérault, F., Le Bec, C., Gross, D. A., Blouin, V., Ryffel, B., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.101 · Cited by 59
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
Engineering humoral immunity as prophylaxis or therapy
Deal, C. E., & Balazs, A. B. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.06.014 · Cited by 27
Inhibition of antigen presentation during AAV gene therapy using virus peptides
Shao, W., Chen, X., Samulski, R. J., Hirsch, M. L., & Li, C. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx427 · Cited by 17
Identification of the murine AAVrh32.33 capsid-specific CD8+ T cell epitopes
Mays, L. E., & Wilson, J. M. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1402 · Cited by 13
Self-citationDa Rocha, S., Bigot, J., Onodi, F., Cosette, J., Corre, G., Poupiot, J., Fenard, D., Gjata, B., Galy, A., & Neildez-Nguyen, T. M. A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.011 · Cited by 12
Metadata
- Authors
- Mays, L. E., Vandenberghe, L. H., Xiao, R., Bell, P., Nam, H.-J., Agbandje-McKenna, M., & Wilson, J. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-05
- Volume
- 182
- Issue
- 10
- Pages
- 6051-6060
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1808026750
- Cited by
- 99
- References
- 19
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.